Cargando…
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
OBJECTIVE: Advanced therapy medicinal products (ATMPs) constitute a class of innovative products that encompasses gene therapy, somatic cell therapy, and tissue-engineered products (TEP). There is an increased investment of commercial and non-commercial sponsors in this field and a growing number of...
Autores principales: | Hanna, Eve, Rémuzat, Cecile, Auquier, Pascal, Toumi, Mondher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973442/ https://www.ncbi.nlm.nih.gov/pubmed/27570614 http://dx.doi.org/10.3402/jmahp.v4.32232 |
Ejemplares similares
-
Advanced therapy medicinal products: current and future perspectives
por: Hanna, Eve, et al.
Publicado: (2016) -
Gene therapies development: slow progress and promising prospect
por: Hanna, Eve, et al.
Publicado: (2017) -
Value added medicines: what value repurposed medicines might bring to society?
por: Toumi, Mondher, et al.
Publicado: (2016) -
Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015) -
New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)